We only discuss the potential negativesHilary, big debt, sec crackdown on nonGAAP, fraud, Brexit, no buyout news, Vrx association, losing market share in some drugs, major investors selling, shorts increasing, and many more potentially negative issues are constantly focussed on and debated on the board.
Where is the news in regards to the new formulations being introduced, adding to revenue, the amco purchase came with a huge debt but also the promise of many new drugs and reformalation that will slowly trickle in. Q2 release should provide us with a better understanding of the integration of amco and its products. That will be the key figure to look for.